Evidence brief: The comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder
Antidepressants are a mainstay of treatment for Major Depressive Disorder (MDD). To guide the choice of antidepressants, clinicians have typically taken a "trial and error" approach, informed by various clinical factors thought to be associated with variable treatment response. But rates o...
| Main Authors: | , , , |
|---|---|
| Corporate Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Washington, DC
Department of Veterans Affairs, Health Services Research & Development Service
2016, May 2016
|
| Series: | Evidence-based synthesis program
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Antidepressants are a mainstay of treatment for Major Depressive Disorder (MDD). To guide the choice of antidepressants, clinicians have typically taken a "trial and error" approach, informed by various clinical factors thought to be associated with variable treatment response. But rates of remission are low and variable, with approximately 11-30% of patients remitting, even after one year of antidepressant treatment. As a result, there is intense interest in identifying additional factors that could help clinicians optimize the effectiveness of available treatments. Genetic variation has long been explored as another potential contributor to individual differences in antidepressant treatment outcome. Whether using genetic information can help predict how an individual might respond to a particular antidepressant - referred to as 'pharmacogenomics' - is of great interest for further advancing precision medicine efforts |
|---|---|
| Item Description: | At head of title: QUERI. |
| Physical Description: | 1 PDF file (i, 31 pages) |